Fig. 7: Combining CBD-IL-12 with STEAP1-mBBζ CAR T cell therapy enhances overall survival and inflammatory cytokine levels. | Nature Communications

Fig. 7: Combining CBD-IL-12 with STEAP1-mBBζ CAR T cell therapy enhances overall survival and inflammatory cytokine levels.

From: Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Fig. 7: Combining CBD-IL-12 with STEAP1-mBBζ CAR T cell therapy enhances overall survival and inflammatory cytokine levels.

a Schematic of the tumor challenge experiment for the RM9-hSTEAP1 disseminated model in hSTEAP1-KI/+ mice investigating the combination of CBD-IL-12 with STEAP1-mBBζ CAR T cell therapy. Cy cyclophosphamide (for preconditioning). Created with BioRender.com. b Serial live BLI of hSTEAP1-KI/ + mice engrafted with RM9-hSTEAP1-fLuc metastases and treated with a single intravenous injection of 5 × 106 mouse untransduced T cells or STEAP1-mBBζ CAR T cells on day 0 with or without CBD-IL-12 treatment weekly. Red X denotes deceased mice. The radiance scale is shown. (c) Plot showing the quantification of total flux over time from live BLI of each mouse in (b). d Kaplan–Meier survival curves of mice in (b) with statistical significance determined by log-rank (Mantel-Cox) test (p = 0.002). e Plots showing serum cytokine levels of IFN-γ (left, p = 0.002) and TNF-α (right, p < 0.0001) based on ProcartaPlex immunoassays from retroorbital bleeds of hSTEAP1-KI/+ mice (n = 4 mice per group) bearing RM9-hSTEAP1-fLuc metastases prior to (day 0) and after treatment (day 8) with untransduced mouse T cells or mouse STEAP1-mBBζ CAR T cells with or without CBD-IL-12 therapy. Error bar represents mean with SEM. For panel (e), p-values were derived from two-way ANOVA with Sidak’s multiple comparisons test. Source data are provided in the Source Data file.

Back to article page